Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Hepatitis C AND Hepatitis C

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    757 result(s) found for: Chronic Hepatitis C AND Hepatitis C. Displaying page 31 of 38.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    EudraCT Number: 2022-002336-31 Sponsor Protocol Number: CT-P17-3.3 Start Date*: 2022-10-20
    Sponsor Name:CELLTRION, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001563-21 Sponsor Protocol Number: IM-T-hLL2-18 Start Date*: 2005-02-02
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002077-76 Sponsor Protocol Number: QGUY/2005/AER 001/-02 Start Date*: 2005-06-13
    Sponsor Name:Aerovance Inc
    Full Title: A Phase 2a Study To Investigate The Effects of Repeated Administration of AeroDerm in subjects with Atopic Eczema.
    Medical condition: Atopic Eczema: a chronic inflammatory pruritic skin disease that follows a relapsing course and is often associated with elevated serum immunoglobulin E (IgE) levels and a personal or family histor...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000163-25 Sponsor Protocol Number: HE2006 Start Date*: 2005-08-04
    Sponsor Name:Research and Enterprise, University of Birmingham
    Full Title: Proteomics and Pharmacokinetics of Adriamycin Following Different Techniques for Chemoembolisation of Hepatocellular Carcinoma (PPATCH) Trial
    Medical condition: Hepatocellular cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002628-96 Sponsor Protocol Number: R-RID Start Date*: 2016-09-21
    Sponsor Name:Imperial College London
    Full Title: A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis
    Medical condition: Decompensated cirrhosis - liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003599-38 Sponsor Protocol Number: 261201 Start Date*: 2013-09-17
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previo...
    Medical condition: Severe hemophilia A (FVIII <1%)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) LT (Completed) CZ (Completed) SE (Completed) ES (Completed) BE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000345-55 Sponsor Protocol Number: A4021016 Start Date*: 2008-06-05
    Sponsor Name:Pfizer Inc 235 East 42nd Street New York, NY 10017
    Full Title: RANDOMIZED, OPEN LABEL, PHASE III TRIAL OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN VERSUS PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Prematurely Ended) FR (Completed) ES (Completed) HU (Completed) DE (Completed) IE (Completed) CZ (Prematurely Ended) SK (Completed) IT (Prematurely Ended) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004904-74 Sponsor Protocol Number: INFQ3003 Start Date*: 2017-09-07
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott’s ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) EE (Ongoing) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) SI (Completed) ES (Completed) FR (Not Authorised) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-000568-32 Sponsor Protocol Number: CLLTX1 Start Date*: 2017-11-07
    Sponsor Name:Universität Köln
    Full Title: Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation
    Medical condition: Patients with poor risk CLL and Richter`s transformation requiring an allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001088-22 Sponsor Protocol Number: CLLR3 Start Date*: 2014-09-23
    Sponsor Name:Städtisches Klinikum München GmbH
    Full Title: A PROSPECTIVE, MULTICENTER, PHASE-II TRIAL EVALUATING EFFICACY AND SAFETY OF BENDAMUSTINE + GA101 (BG) IN PATIENTS WITH RELAPSED CLL FOLLOWED BY MAINTENANCE THERAPY WITH GA101 FOR RESPONDING PATIENTS.
    Medical condition: Relapsed Chronic lymphocytic leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002492-17 Sponsor Protocol Number: CLL-RT1 Start Date*: 2019-11-13
    Sponsor Name:Universität zu Köln
    Full Title: A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment ...
    Medical condition: Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008975 Chronic lymphocytic leukaemia variants LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-006083-57 Sponsor Protocol Number: CA184-025 Start Date*: 2006-10-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol...
    Medical condition: Stage III, IV metastatic advanced melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Prematurely Ended) AT (Completed) HU (Completed) FI (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003528-62 Sponsor Protocol Number: EDP305-201 Start Date*: 2018-12-05
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis...
    Medical condition: Primary Biliary Cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003854-99 Sponsor Protocol Number: CLL17 Start Date*: 2021-06-11
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patie...
    Medical condition: Patients with previously untreated CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002268-26 Sponsor Protocol Number: CTN240 Start Date*: 2013-01-02
    Sponsor Name:University Health Network, Toronto General Hospital
    Full Title: Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)
    Medical condition: Coinfection of Human Immunodeficiency Virus and Herpes Simplex Virus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003984-23 Sponsor Protocol Number: BOC-HIV Start Date*: 2013-04-19
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: A phase III open label study to evaluate safety and efficacy of Boceprevir-response guided therapy in controlled HIV patients with chronic hepatitis C genotype 1 infection who failed previously to ...
    Medical condition: HCV and HIV seropositive coinfection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10065949 HCV coinfection LLT
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001514-26 Sponsor Protocol Number: UIAPB-PRPULCERAS-2014 Start Date*: 2015-01-15
    Sponsor Name:Comarca Ezkerraldea-Enkarterri (OSAKIDETZA)
    Full Title: Efficacy of Autologous Platelet-Rich Plasma in the treatment of vascular ulcers in Primary Care: Clinical trial phase III.
    Medical condition: Patients with venous leg ulcers, between 40-100 years old, assigned to ten health centers in the county Ezkerraldea-Enkarterri Osakidetza Basque Health Service.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10040796 Skin and subcutaneous tissue ulcerations HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002713-30 Sponsor Protocol Number: GS-US-292-1825 Start Date*: 2016-04-05
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection in Subjects on Chronic Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004301-27 Sponsor Protocol Number: NIBIT-M2 Start Date*: 2012-11-08
    Sponsor Name:FONDAZIONE NIBIT
    Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis
    Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 08:43:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA